LAVAL, Quebec, March 9, 2021 /PRNewswire/ -- Bausch Health
Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company")
has published a presentation that Joseph C.
Papa, chairman and CEO, Sam
Eldessouky, senior vice president and corporate controller,
and Arthur J. Shannon, senior vice
president and head of Investor Relations and Communications, are
scheduled to present at the Barclays Global Healthcare Conference
today, March 9, 2021, at 2:25 p.m. ET.
The presentation, which provides an update on Bausch Health's
current pipeline for Salix, including an update regarding its
rifaximin clinical development efforts, is available on the
Investor Relations page of the Bausch Health Companies Inc. website
at: https://ir.bauschhealth.com/events-and-presentations/2021. A
live webcast and audio archive of the event will also be available
on the Investor Relations page of the Company's website.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company
whose mission is to improve people's lives with our health care
products. We develop, manufacture and market a range of
pharmaceutical, medical device and over-the-counter products,
primarily in the therapeutic areas of eye health, gastroenterology
and dermatology. We are delivering on our commitments as we build
an innovative company dedicated to advancing global health. More
information can be found at www.bauschhealth.com.
Forward-looking Statements
This news release may contain forward-looking statements, which
may generally be identified by the use of the words "expects,"
"intends," "plans," "should," "could," "would," "potential" or
"target" and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks and uncertainties discussed in
Bausch Health's most recent annual report on Form 10-K and detailed
from time to time in Bausch Health's other filings with the U.S.
Securities and Exchange Commission and the Canadian Securities
Administrators, which factors are incorporated herein by reference.
They also include, but are not limited to, risks and uncertainties
caused by or relating to the evolving COVID-19 pandemic, and the
fear of that pandemic and its potential effects, the severity,
duration and future impact of which are highly uncertain and cannot
be predicted, and which may have a material adverse impact on
Bausch Health, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
Investor Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bausch-health-publishes-pipeline-update-for-the-barclays-global-healthcare-conference-301243006.html
SOURCE Bausch Health Companies Inc.